Until now, the main findings regard the above-mentioned GNbAC1 monoclonal Ab, targeting HERV-W/MSRV Env proteins and proposed as innovative therapy for MS and type I diabetes. This evidence concerns the gene ERVW-1 and myeloid sarcoma.